Newer blood thinners tied to less bleeding in sickle cell disease study

Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults with sickle cell disease (SCD) treated for dangerous blood clots, according to a study led by researchers in Saudi Arabia.

However, no significant differences were seen between the treatments in overall clinical outcomes or in the risk of developing additional blood clots.

The study, “Management of venous thrombosis in sickle cell disease: a comparative study on the use of DOACs and warfarin,” was published in Research and Practice in Thrombosis and Haemostasis.